Assaying

Eveliina Taavitsainen, Maarit Kortesoja, Tanja Bruun, Niklas G Johansson, Leena Hanski

Open access · goldAbstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.5field-weighted citation impact, top 38% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 9 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Eveliina TaavitsainenDrug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland.ORCID 0000-0003-1337-5998

Maarit KortesojaDrug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland.

Tanja BruunDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland.ORCID 0000-0001-7956-368X

Niklas G JohanssonDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland.ORCID 0000-0002-8226-4813

Leena HanskiDrug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland.ORCID 0000-0002-3121-8542

University of Helsinki · FI

Funding

Suomen Kulttuurirahasto ET and LH

6 · The paper itself

Abstract

Antibiotic-tolerant persister bacteria involve frequent treatment failures, relapsing infections and the need for extended antibiotic treatment. The virulence of an intracellular human pathogen

Indexed as

AzithromycinBiological AssayChlamydophila pneumoniaeCyclooctanesGlutathioneHumansKineticsLignansMacrophagesOxidation-ReductionPhenotypePolycyclic CompoundsReactive Oxygen SpeciesTHP-1 CellsAzithromycinCyclooctanesdibenzocyclooctadiene lignanGlutathioneLignansPolycyclic CompoundsReactive Oxygen Speciesschizandrinadjuvant therapyantibacterial agentbacterial persistencedormancyglutathionenatural product

Identifiers

PMID31940776

DOI10.3390/molecules25020294

PMCPMC7024427

OpenAlexW2999191232

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.